GlassScriptPhysician profile
Nathaniel Justin Ernstoff
NPI 1306189147
$36,559.07
in general payments reported to CMS, 2019-2025
44 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $881 · 2021: $2,720 · 2022: $3,014 · 2023: $3,153 · 2024: $14K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $9,593 · Travel and Lodging: $1,830 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,281.25 |
| Food and Beverage | $9,593.47 |
| Travel and Lodging | $1,829.63 |
| Education | $118.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $21,196.87 | 2024-2025 | Zenpep |
| Abbvie INC. | $3,287.19 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,589.67 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,506.20 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,008.27 | 2020-2025 | Xifaxan, Plenvu, Uceris |
| Ardelyx, INC. | $832.00 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $653.11 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $605.45 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $594.37 | 2020-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $581.00 | 2022-2025 | |
| Madrigal Pharmaceuticals | $570.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $455.44 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $295.29 | 2020-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $268.11 | 2022-2024 | Dupixent |
| Boston Scientific Corporation | $251.48 | 2020-2025 | Resolution 360 Clip, General - Polypectomy, General - Hemostasis |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $251.42 | 2020-2025 | Ocaliva |
| Celltrion USA INC. | $249.37 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Braintree Laboratories, INC. | $228.52 | 2020-2025 | Suflave, Sutab |
| Laborie Medical Technologies Corp. | $223.37 | 2022-2023 | |
| Lilly USA, LLC | $204.71 | 2024-2025 | Omvoh, Zepbound |
| Evoke Pharma, INC. | $193.45 | 2021-2024 | Gimoti |
| Alnylam Pharmaceuticals INC. | $173.39 | 2020 | |
| Pfizer INC. | $171.41 | 2022-2025 | |
| Vivus LLC | $154.74 | 2021-2025 | Pancreaze, Qsymia |
| Janssen Scientific Affairs, LLC | $134.75 | 2022 | |
| Shire North American Group INC | $121.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $95.28 | 2021 | |
| Pharmacosmos Therapeutics INC. | $90.85 | 2022-2025 | Monoferric |
| Ferring Pharmaceuticals INC. | $68.03 | 2022-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $65.79 | 2021-2023 | |
| Organon LLC | $57.94 | 2021-2023 | Renflexis |
| Medtronic, INC. | $56.55 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $38.32 | 2022-2024 | Lesionhunter |
| Amgen INC. | $38.22 | 2021 | |
| Capsovision, INC. | $36.65 | 2023 | Capsocam Plus |
| Cumberland Pharmaceuticals, INC. | $34.50 | 2022-2023 | Kristalose |
| Fresenius Kabi USA, LLC | $34.19 | 2023-2024 | Idacio |
| Merck Sharp & Dohme LLC | $26.81 | 2020-2021 | |
| Mylan Institutional INC. | $22.45 | 2023 | Hulio |
| Vibrant Gastro, INC. | $19.08 | 2024 | Vibrant Starter Kit |
| Endo Pharmaceuticals INC. | $18.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.43 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $18.16 | 2025 | Iqirvo |
| Ucb, INC. | $17.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Ernstoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.